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www.embomolmed.org EMBOThe telomeric amplicon at 8p12 is common in oestrogen receptor-positive (ERþ)
breast cancers. Array-CGH and expression analyses of 1172 primary breast
tumours revealed that ZNF703 was the single gene within the minimal amplicon
and was amplified predominantly in the Luminal B subtype. Amplification was
shown to correlate with increased gene and protein expression and was associ-
ated with a distinct expression signature and poor clinical outcome. ZNF703
transformed NIH 3T3 fibroblasts, behaving as a classical oncogene, and regulated
proliferation in human luminal breast cancer cell lines and immortalized human
mammary epithelial cells. Manipulation of ZNF703 expression in the luminal
MCF7 cell line modified the effects of TGFb on proliferation. Overexpression of
ZNF703 in normal human breast epithelial cells enhanced the frequency of in
vitro colony-forming cells from luminal progenitors. Taken together, these data
strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer.Cambridge, UK.







Mol Med 3, 167–180INTRODUCTION
In human cancers, genes altered by amplification and
concomitant overexpression are considered candidate onco-
genes (Santarius et al, 2010). However, amplicons often include
several candidates making it difficult to delineate the true cancer
gene. Amplification (frequently high-level) of the proximal
chromosomal arm 8p (8p12) is common in breast cancer (Chin
et al, 2006). There are four amplification cores consistently
identified at 8p12 with the most telomeric of these cores being
the most common and characterized originally by our group as
containing only 6 genes (Garcia et al, 2005), a finding
consistently confirmed by other studies (Adelaide et al, 2007;
Gelsi-Boyer et al, 2005; Haverty et al, 2008; Kwek et al, 2009;
Prentice et al, 2005). Correlation between copy number and
gene expression was previously used to exclude GPR124,
leaving as candidates the following five genes, ordered from
telomere to centromere: ZNF703, ERLIN2, PROSC, BRF2, and 2011 EMBO Molecular Medicine 167
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168RAB11FIP1 (Adelaide et al, 2007; Garcia et al, 2005; Gelsi-Boyer
et al, 2005; Haverty et al, 2008; Kwek et al, 2009). Despite this
work, the identity of the driver oncogene at the most telomeric
amplicon at 8p12 remains unknown. This has made functional
characterization of the putative driver oncogene extremely
difficult since several genes have to be analysed. We
hypothesized that using higher resolution platforms for copy
number profiling to characterize a larger number of cancers than
what has been performed to date would allow a more precise
mapping of the minimal amplicon. Furthermore, parallel
analyses of the same cancers with gene expression arrays could
then be used to further define putative targets by a more robust
correlation analysis between copy number and gene expression.
In addition, this was used to classify breast cancers into one of
the intrinsic molecular subtypes (Luminal A, Luminal B, Her2,
Basal-like and Normal-like) (Sorlie et al, 2003) and therefore
investigate preferential amplification across these. Oestrogen
receptor-positive (ERþ) breast cancers are almost all luminal
with the better prognosis ones usually classifying as Luminal A
and the more aggressive, higher grade, and less responsive to
hormone therapy being more commonly Luminal B. The Her2
subtype identifies mostly the oestrogen receptor-negative
(ER), ERBB2-amplified cancers, and Basal-like cancers are
mostly ER and overexpress basal cytokeratins.
In this study, we profiled two cohorts of 171 and 1001 primary
breast cancers to further refine the minimal amplicon, and have
functionally characterized ZNF703, the sole candidate that
emerged from these studies, as the likely driver oncogene at
distal 8p12.RESULTS
The 8p12 telomeric amplicon drives expression in luminal
primary cancers and breast cancer cell lines
We previously profiled copy number aberrations in a cohort of
171 primary breast tumours (the NT-series—see Materials and
Methods) and in a panel of 49 breast cancer cell lines, using
customized oligonucleotide microarrays containing 27,801 60-
mer oligonucleotide probes (herein called the 28k-array) with
unique map positions (Chin et al, 2007). A joint analysis of the
segmented copy number data from primary tumours and breast
cancer cell lines delineated the boundaries of a common
minimal 8p12 telomeric amplicon of 500–600 kb in size
spanning ZNF703, ERLIN2, PROSC, GPR124, BRF2, and RAB11FIP.
Gains of this minimal amplicon were observed in 32% of primary
tumours (10% had amplifications) and 24% of cell lines (5% had
amplifications), confirming our earlier results in a smaller series
using lower resolution BAC arrays (Garcia et al, 2005).
The correlation between copy number and gene expression
was assessed for each of these genes using Illumina BeadArrays
to profilemRNA expression in 99 tumours from theNT-series for
which RNA of appropriate quality was available (Fig 1A).
Microarray expression data were validated by RT-QPCR (Fig
S1A). For each gene except GPR124, we observed a clear
increase in gene expression between copy number neutral,
gained, and amplified ERþ cases. The ER cases were almost 2011 EMBO Molecular Medicineexclusively copy number neutral for this region (53/54).GPR124
expression was similar across all categories and expression was
copy number-independent, hence this gene was again ruled out
as the driver for this amplicon. We observed a similar
relationship between gene dosage and expression for the six
genes within the 8p12 amplicon in a set of 39 breast cancer cell
lines also profiled on the Illumina platform (Fig S1B). The
corresponding Pearson correlation coefficients were as follows:
ZNF703 (0.72), ERLIN2 (0.79), PROSC (0.78), GPR124 (0.03),
BRF2 (0.87), and RAB11FIP1 isoforms (0.35 to 0.73), similarly
eliminating GPR124 as a driver oncogene in cell lines. The
slightly lower correlation of ZNF703 copy number and gene
expression compared to the other 4 genes can be explained by a
group of 5 ERþ cell lines (KPL-1, HCC1419, MDA-MB-361, T47D
and IBEP-1), which overexpress ZNF703 in a copy-neutral
background. No similar outliers were found for the other copy
number-driven genes in the amplicon. Removal of these
samples resulted in an increase of the Pearson correlation
coefficient to 0.9. We also noted that out of the 6 genes within
the amplicon, ZNF703 is the only one with significantly lower
expression in ER tumours (Fig 1A).
Further examination of the expression levels of the six genes
across the breast cancer molecular subtypes defined by the
PAM50 classifier (Parker et al, 2009) revealed that all but
GPR124 and RAB11FIP1 are significantly overexpressed in
Luminal B compared to Luminal A tumours (Fig 1B, Wilcoxon
rank sum test p< 0.05). Furthermore, ZNF703, BRF2, and
RAB11FIP1 expression levels were significantly higher in
Luminal B compared to Basal-like tumours, while GPR124
was significantly lower (Fig 1B).
Narrowing of the minimal amplicon in 1001 breast cancers
profiled using high-resolution SNP arrays
The design of the 28k-array CGH platform described above was
gene-centric, almost always with a single probe per gene,
limiting the ability to confidently map copy number segments
encompassed by a few probes. We therefore used copy number
data from a further 1001 primary breast cancers, the MB-series
(Curtis et al, manuscript in preparation), profiled using Affymetrix
SNP 6.0 arrays to robustly define the telomeric and centromeric
boundaries of the minimal amplicon (Fig 2). In at least 20 primary
tumours, the telomeric boundary was placed in the750kb ‘gene
desert’ separating KCNU1, outside the amplicon, and ZNF703,
inside the amplicon. The centromeric boundary could be
confidently mapped to an interval that separates the 30 end of
the short isoform of ERLIN2 and the 50 end of PROSC. The
consensus minimal amplicon defined by these boundaries
therefore contained only two genes: ZNF703 and ERLIN2. In 5
cases (MB-0636,MB-2854,MB-5427,MB-0628, andMB-5291), the
minimal amplicon included only these two genes. Copy number
gain or amplification of ZNF703/ERLIN2 was detected in 23.2%
(8.7% amplification) of ERþ tumours and only 11.7% (2%
amplification) of ER tumours. Alteration of this region wasmost
prevalent in Luminal B tumours (32.5% gain or amp, 13%
amplification), less common in Luminal A tumours (18.7% gain
or amp, 6.4% amplification), and present in less than 14% (3.4%
amplification) of tumours in the remainder of subtypes (Fig S2A).EMBO Mol Med 3, 167–180 www.embomolmed.org
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Figure 1. Expression of genes within the telomeric 8p12 amplicon is copy number-driven and highest in Luminal B tumours.
A. Boxplots of normalized gene expression in 99 tumours (obtained using Illumina arrays) in relation to copy number (CN) state (determined using 28k-arrays).
B. Boxplots of normalized expression in tumours according to the intrinsic subtype (Luminal A¼ 43; Luminal B¼22; Normal-like¼ 13; Her2-enriched¼24;
Basal-like¼ 24), based on the PAM50 classifier.Interestingly, amplifications of ZNF703/ERLIN2 and ERBB2 in
luminal tumours were nearly mutually exclusive (Fig S2B).
Copy number driven expression of both ZNF703 and ERLIN2,
and their association with ER status and the intrinsic subtypes
was confirmed in the 1001 primary tumours from the MB-series,
validating the predominant association with Luminal B breast
cancers (Fig S2C and D). Additionally, immunohistochemical
staining of both proteins in normal human breast tissue was
done using antibodies tested for performance and specificity
(see Supporting information for details). ZNF703 protein
expression was detected at low levels in the nucleus of scattered
normal luminal epithelial cells (Fig S2E). In contrast, ERLIN2
was expressed in a cytoplasmic peri-nuclear pattern in both
epithelial (luminal and basal) and stromal cells (Fig S2F). In
breast cancers, while ZNF703 protein expression correlatedwith
ZNF703 mRNA levels and was significantly higher in ERþ
tumours with amplification, the ERLIN2 protein expression
pattern did not correlate with either ERLIN2 gene expression or
copy number (Fig S2G). These data strongly favour ZNF703 as
the likely candidate driver oncogene of the amplicon.
ZNF703 is the only gene within the amplicon in two Luminal
B breast cancers
We noted that there was a single tumour out of 1001 analysed
using Affymetrix arrays, MB-0884, with exclusive amplification
of ZNF703 (Fig 2, top panel). None of the other 18 genes in thewww.embomolmed.org EMBO Mol Med 3, 167–180850 kb interval spanned by ZNF703 and C8ORF86 (containing all
four 8p12 amplification cores mentioned in the Introduction)
appeared exclusively as a single-gene amplicon in these 1001
tumours (data not shown). This prompted a careful reanalysis of
the 28k-array data revealing that one of the original 171 cases
(NT-2347) had a log2 value for the ZNF703 probe consistent with
high-level amplification, but was missed by the segmentation
algorithm. DNA from this case was then hybridized to a 244K
Agilent oligonucleotide array as well as the Affymetrix SNP 6.0
array, confirming a focal high-level amplification of ZNF703
(Fig 2, bottom panel and Fig S2H). In both tumours, ZNF703was
overexpressed, while ERLIN2 exhibited normal/reduced expres-
sion levels (Fig 2, bottom panel). The two tumours were
classified as Luminal B and had few other genomic aberrations
(Fig S2I). These genomic and transcriptomic data firmly
establish ZNF703 as the sole candidate driver oncogene of the
8p12 telomeric amplicon that occurs in about 1/3 of Luminal B
breast cancers.
ZNF703-amplified tumours are associated with a distinctive
transcriptional signature and have worse clinical outcome
We next asked whether breast cancers with ZNF703 amplifica-
tion have distinctive genomic, transcriptomic or clinical features
that separate them from other luminal tumours.
A recent analysis of 4 breast cancer cohorts, which included
the NT-series, revealed that 8p12 amplified tumours, frequently 2011 EMBO Molecular Medicine 169
Research Article
ZNF703 is a Luminal B breast cancer oncogene
Figure 2. Mapping the 8p12 amplicon using high-resolution SNP arrays narrows its core to ZNF703. Copy number and expression mapping of the 8p12 distal
amplicon for selected samples from the MB-series and sample NT-2347 from the NT-series. ER status (determined by IHC), intrinsic subtype (using PAM50
classifier) are shown colour coded on the left. Colour bars on the right indicate log2 values. Top panel: IGV heatmap (http://www.broadinstitute.org/igv) of
segmented copy number data for individual samples used to define the centromeric and telomeric boundaries of the amplicon. Bottom panel: Focused view of the
two tumours in which the amplicon was restricted to ZNF703 illustrating probe-level copy number data (log2, black dots) and normalized expression values.
170including ZNF703, had high complex arm aberration indices
(Russnes et al, 2010). We observed a similar trend in tumours
with ZNF703 amplification from the MB-series analysed here
(examples in Fig S2J). These patterns are characteristic of breast
cancers with higher genomic instability and more aggressive
clinical behaviour.
To characterize the transcriptional landscape of Luminal B
tumours with ZNF703 amplified/overexpressed, genes differ-
entially expressed in these breast cancers relative to ZNF703
copy neutral cases were identified (Table S1A) and subject to
pathway analyses. Tumours with elevated ZNF703 levels were 2011 EMBO Molecular Medicinecharacterized by alterations in a lipid metabolism and
detoxification pathway in which DHRS2 (Hep27), a short-chain
dehydrogenase family member, acts as a key nuclear signalling
component (Fig 3A; Fig S3A). Other components of the
detoxification signature include the UDP-glucuronosyltrans-
ferases, UGT2B11 and UGT2B7. UGT2B11 regulates the levels of
oestrogen metabolites (Turgeon et al, 2001). Notably, this
detoxification signature was also observed in breast cancer cell
lines with ZNF703 amplification or upregulation when a similar
analysis was done (Fig S3B and C; Table S1B). These data show
that primary luminal tumours and luminal breast cancer cellEMBO Mol Med 3, 167–180 www.embomolmed.org
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Figure 3. ZNF703-amplified tumours are characterized by a lipid metabolism and detoxification gene expression signature and have poor clinical
prognosis.
A. Graphical representation of the key enzymes andmolecules involved in canonical lipidmetabolism and detoxification pathways enriched for amongst ZNF703-
amplified or overexpressing tumours in the MB-series. Dark red represents molecules whose expression levels are up-regulated greater than 1.5-fold, whereas
dark blue representsmolecules whose expression levels are down-regulated greater than 1.5-fold. All genes/molecules are significantly differentially expressed
with FDR-adjusted p-values< 0.01. Arrows represent biological relationships between molecules and the various shapes represent the functional class of the
gene product.
B. Kaplan–Meier plots (Breast cancer-specific survival, BCSS) and p-values based on a log-rank test are indicated for the comparison of ZNF703 (8p12)-amplified
(AMP) versus neutral (NEUT) cases amongst ER-positive tumours.lines with ZNF703 amplification/overexpression have a dis-
tinctive gene expression signature.
Amplification of 8p12 in breast cancers has previously been
associated with poor prognosis (Gelsi-Boyer et al, 2005;
Letessier et al, 2006; Prentice et al, 2005), and we thereforewww.embomolmed.org EMBO Mol Med 3, 167–180asked whether ZNF703 amplification was associated with worse
clinical outcome in the two cohorts described herein. In both
series, we observed that ZNF703 amplification was associated
with reduced breast cancer specific survival in ERþ cancers
(Fig 3B). 2011 EMBO Molecular Medicine 171
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mouse fibroblast primary focus formation assay
To determine whether ZNF703 had oncogenic properties, we
examined whether ectopic ZNF703 expression could transform
NIH 3T3 mouse fibroblasts in proliferation, primary focus
formation, and soft agar assays. Cells expressing KrasG12D4B
were used as a positive control for the primary focus formation
assay (data not shown). Western blot analysis was used to
confirm protein expression in transfected cells (Fig 4A, left
panel). ZNF703 promoted proliferation of NIH 3T3 cells (Fig 4A,
right panel). NIH 3T3 cells ectopically expressing ZNF703
exhibited a significant loss of contact inhibition (Fig 4B, left
panel), with mock transfected cells displaying no focus
formation and ZNF703-overexpressing NIH 3T3 cells forming
hundreds of foci per plate. NIH 3T3 cells ectopically expressing
ZNF703 also exhibited significant induction of anchorage-
independent growth (Fig 4B, right panel). Taken together, these
data demonstrate that ZNF703 promotes proliferation and
transformation of NIH 3T3 cells.
ZNF703 regulates proliferation in breast epithelial cells
Next, to determine whether ZNF703 could regulate proliferation
in breast epithelial cells, we manipulated ZNF703 expression in
a luminal breast cancer cell line, MCF7, with neutral copy
number and an intermediate level expression of ZNF703, using
RNAi and lentiviral overexpression (Fig S4). Knockdown and
overexpression of ZNF703 protein was verified using Western
blotting (Fig 4C, right panel). In lenti-ZNF703 transfected cells,
ZNF703 protein levels were similar in si-control and si-ZNF703
cells, since the siRNA targets the 30UTR of the endogenous
protein. We used BrdU incorporation to measure cell prolifera-
tion and these experiments showed that upon knockdown of
ZNF703 protein there was a significant decrease in BrdU
incorporation as compared to control cells with baseline levels
of ZNF703 (Fig 4C, left panel). There was no significant change
in proliferation of MCF7 cells where ZNF703 protein was
overexpressed.
We also used RNAi to knockdown ZNF703 in HCC1500 cells,
which display amplification and overexpression of ZNF703, and
detected decreased proliferation using the BrdU assay (Fig 4D).
Finally, we wanted to determine whether ZNF703 over-
expression regulated proliferation in non-malignant humanFigure 4. ZNF703-mediated transformation of NIH 3T3 mouse fibroblasts and
A. Ectopic ZNF703 expression in NIH 3T3 cells and proliferation. Left panel: Weste
panel: Proliferation curve of NIH 3T3 fibroblasts ectopically expressing ZNF703.
in triplicate is shown.
B. NIH 3T3 transformation assays. Left panel: Focus formation assay showing foc
were taken after GIEMSA staining at low and high magnification. Right pane
photographed and counted after 4 weeks in 10 random fields (Magnification
performed in duplicate is shown.
C. Proliferation in MCF7 cells with manipulated ZNF703 expression. MCF7 cells we
were then transfected with scrambled or siRNA oligonucleotides targeting endo
for RNA extraction, or lysed and cross-linked for Western blot and chromatin
incorporation assay. Right panel: Western blot for ZNF703 and Actin.
D. Proliferation in HCC1500 cells. Bar plot (mean and standard deviation) of BrdU i
siRNA.
E. Proliferation in HMECs. FACS dot plots and bar chart with results of cell cycle ana
www.embomolmed.org EMBO Mol Med 3, 167–180mammary epithelial cells (HMECs) (Fig 4E). For these
experiments, we used the 184-hTERT immortalized normal
mammary epithelial cell line (Horikawa et al, 2002; Stampfer et
al, 2001). In 184-hTERT cells infected with lenti-ZNF703, where
ZNF703 overexpression was verified by RT-QPCR, a statistically
significant 1.92-fold increase in the percentage of cells in S-
phase (as measured by EdU incorporation) was observed as
compared to lenti-control infected cells. HMECs overexpressing
ZNF703 also showed statistically significant decrease of G0/G1
cells and increase of G2/M cells (Fig 4E).
In summary, these experiments show that modulation of
ZNF703 expression regulates proliferation in human breast
epithelial cells.
Modulation of ZNF703 protein expression alters the effects of
TGFb on proliferation of MCF7 cells
Gene expression arrays were used for transcriptional profiling of
the MCF7 cells with manipulated ZNF703 expression by RNAi or
overexpression (Fig S4). As expected, ZNF703was one of the top
upregulated genes upon its overexpression in MCF7 cells
(Fig 5A, top panel). Importantly, amongst the genes whose
expression levels were significantly altered (222 in total, Table
S2) as a result of ZNF703 overexpression in MCF7 cells, a subset
was also differentially expressed in primary tumours with
ZNF703 amplification/overexpression: DHRS2, HPGD, ID2,
IRX5, SLOM1, NLK, and EFHD1, which were significantly up-
regulated, and ZFP36L2, UGT2B7, and RALB, which were down-
regulated (Table S1A). Another gene significantly down-
regulated in MCF7 cells was the cell cycle inhibitor CDKN2B.
In contrast, in the ZNF703-knockdown cells there were few
differentially expressed genes (Fig 5A, bottom panel), none
reached significance using the stringent criteria used above.
However, ZNF703was one of the top downregulated genes. One
of the top upregulated genes was transforming growth factor
beta receptor II (TGFBR2). TGFBR2 was also expressed at lower
levels in ERþ primary breast cancers with ZNF703 over-
expression (Table S3). We validated a representative selection
of differentially expressed genes by RT-QPCR, including
CDKN2B and TGFBR2, confirming the robustness of results
from the microarray experiments (Fig S5).
TGFb is a well known potent inhibitor of proliferation in
MCF7 cells. TGFBR2 and CDKN2B, found differentiallyproliferation effects in human breast epithelial cells.
rn blot showing ectopic expression of ZNF703 in NIH 3T3 infected cells. Right
Themean and standard deviation of one representative experiment performed
i formed by ectopic expression of ZNF703. Representative pictures of the foci
l: Bar plot showing counts of colonies in soft agar assay. Colonies were
: 20). The mean and standard deviation of one representative experiment
re infected either with a lenti-ZNF703 or lenti-control. Lentiviral infected cells
genous ZNF703, grown for 48 h and parallel replicate plates (in triplicate) used
IP experiments. Left panel: Bar plot (mean and standard deviation) of BrdU
ncorporation assay of HCC1500 cells transfected with either control or ZNF703
lysis of lenti-control and lenti-ZNF703 infected 184-hTERT immortalized cells.
 2011 EMBO Molecular Medicine 173
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Figure 5. ZNF703 modulates TGFb proliferation responses in MCF7 cells.
A. Genes differentially expressed in MCF7 cells with ZNF703 manipulation. Top panel: Clustered heatmap of differentially expressed genes in MCF7 cells
overexpressing ZNF703. Bottom panel: Volcano plot showing differentially expressed genes in MCF7 ZNF703 knockdown.
B. Proliferation of MCF7 cells with ZNF703 overexpression versus control in response to TGFb. Left panel: Bar plot of BrdU incorporation assay. Right panel:
RT-qPCR for TGFb-pathway genes.
C. Proliferation of MCF7 cells with ZNF703 knockdown versus control in response to SB-431542. Left panel: Bar plot of BrdU incorporation assay. Right panel:
Western blot for pSMAD2 and total SMAD2.
D. TGFBR2 chromatin immuno-precipitation (ChIP). Left panel: Schematic representation of the genomic regions around the TGFBR2 and PRKCE genes and
relative location of primer sequences used for PCR of immunoprecipitated chromatin. Middle panel: Fold enrichment measured by real-time PCR of the
regulatory regions described above in ZNF703 versus IgG control ChIP from untransfected MCF7 cells. The data are the average (SD) of three individual
replicates. Right panel: Fold enrichment measured by real-time PCR in ChIP for p300 and HDAC-1 from si-control or si-ZNF703 transfected MCF7 cells. Data
show the average of three independent replicates Std Dev.  denotes p< 0.05.
174  2011 EMBO Molecular Medicine EMBO Mol Med 3, 167–180 www.embomolmed.org
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genes. We therefore asked whether in MCF7 cells with
overexpression or knockdown of ZNF703, there would be
modulation of proliferation, measured using BrdU incorpora-
tion, in response to activation or inhibition of the TGFb-pathway
(Fig 5B and C). We saw that upon treatment with recombinant
TGFb1, MCF7 cells display significantly decreased proliferation,
as expected, and this effect was not seen in cells with ZNF703
overexpression (Fig 5B, left panel). This was accompanied by
reduced TGFBR2 transcript levels and abrogation of upregula-
tion of TGFb target genes (TGFBI, transforming growth factor,
beta-induced and PAI1, plasminogen activator inhibitor type 1)
(Fig 5B, right panel). In the reverse experiment, we observed
that, when we treated ZNF703-knockdown MCF7 cells with the
TGFb-pathway inhibitor SB-431542, there was no longer a
decrease in proliferation, as observed in control cells (Fig 5C, left
panel). Western blotting (Fig 5C, right panel) of extracts from
these cells showed a modest increase in pSMAD2 in si-ZNF703
cells compared with si-control cells and complete absence of
pSMAD2 in cells treated with the inhibitor. We quantified the
western blot bands to determine the proportion of SMAD2 that
was phosphorylated using Image Quant TL (GE Healthcare) and
this confirmed that in si-ZNF703 cells, there was a significant
measurable 10% absolute increase in pSMAD2 compared to
control cells. These results reveal that, upon modulation of
ZNF703 protein expression, the effect of TGFb on the
proliferation of MCF7 cells is altered.
We next mapped ZNF703 binding to the locus of the putative
target gene TGFBR2 using chromatin immunoprecipitation
(ChIP) (Fig 5D). Primers were designed against the promoter
and to a region shown to possess H3K4me1 or H3K4me3 histone
modifications around the locus from public Encode datasets (Fig
5D, left panel). Included as a control were primers against a
region containing H3K4 activity in the PRKCE gene, which is not
altered by ZNF703. In native MCF7 cells, we found ZNF703
binding at regionswithin the TGFBR2 gene, but not at the control
region within the PRKCE gene (Fig 5D, middle panel). To
determine whether ZNF703 was binding in a repressive manner
to the regulatory regions interrogated, we assessed binding of
the histone acetyl transferase p300 and the histone deacetylase
HDAC1 to these regions in the presence or knockdown of
ZNF703 (Fig 5D, right panel). In the si-control transfected cells,
we observed HDAC1 binding to the regions also bound by
ZNF703, suggesting that ZNF703maymediate active repression.
In cells transfected with si-ZNF703, we observed a decrease in
HDAC1 binding, alongside recruitment of p300, and RT-qPCR
showed upregulation of TGFBR2 (Fig S5), hence indicative of
active transcription. These ChIP results show that modulation of
ZNF703 in breast cancer cells alters histone modifier protein
recruitment to TGFBR2 cis-regulatory elements, resulting in a
shift from a repressive state to a transcriptionally active state
upon knockdown of ZNF703.
ZNF703 expression in primary human mammary epithelium
drives luminal progenitors and represses basal progenitors
The strong association of ZNF703 amplification/overexpression
with luminal breast cancers prompted us to askwhether ZNF703www.embomolmed.org EMBO Mol Med 3, 167–180expression could affect the ability of normal luminal and basal
progenitors in primary human mammary epithelium to
differentiate in vitro. The presence of mammary progenitor
cells within adult human breast tissue can be assayed and
quantified using colony-formation assays. These include cells
that are myoepithelial/basal-restricted, luminal-restricted, or
bipotent, the latter representing the most primitive cell within
the breast lineage hierarchy that can be quantified in vitro
(Stingl et al, 2001). We were able to enrich for these progenitor
cell fractions following the parameters described by Stingl et al.
Briefly, reduction mammoplasty tissue obtained from 6
independent patient samples was subjected to a series of
enzymatic dissociations to obtain a single cell suspension. Using
4-color flow cytometry, cells were initially depleted of
haematopoietic and endothelial cells based on lack of CD45
and CD31 expression, respectively. Following this, EpCam and
CD49f expression was used to prospectively fractionate the
remaining epithelial cells into luminal progenitor (EpCamþ,
CD49fþ) and bi-potent progenitor (EpCam, CD49fþ) enriched
fractions (Fig 6A).We infected the enriched pools of luminal and
basal mammary epithelial progenitors with either lenti-ZNF703
or lenti-control virus. The assay endpoint was colony count,
which was done in a total of 24 plates (4 per patient-derived
sample: two for luminal and two for basal progenitors,
respectively control and ZNF703 transfected) (Supp. Table 4).
An omnibus test of equality of ZNF703 infected counts for the
luminal and basal fractions, adjusting for control counts,
showed strong evidence of a difference in colony-formation
counts between the two fractions (ANCOVA F(2,8)¼ 11.419,
p¼ 0.0045) (Fig 6B). Within fractions and counting differen-
tiated luminal or basal colonies as the assay endpoint, the
luminal progenitor enriched fraction showed a statistically
significant 2.23-fold increase in colony counts when infected
with lenti-ZNF703, as compared with the control (p< 0.05; 95%
CI adjusted for multiple comparisons: 1.48-2.98) (Fig 6C). The
basal progenitor enriched fraction showed a statistically
significant 2.60-fold decrease in colony counts (p< 0.05; 95%
CI adjusted for multiple comparisons: 0.05–0.72) (Fig 6C). These
data robustly show that ZNF703 differentially regulates luminal
and basal progenitors in primary human mammary epithelium.DISCUSSION
We have exploited the power of high-resolution copy number
profiling in a large number of breast cancers (from two
independent series of primary tumours and a panel of breast
cancer cell lines) to significantly narrow themost telomeric 8p12
amplicon down to only two genes (ZNF703 and ERLIN2) and to
identify two cases where ZNF703 was the only gene within the
amplicon (Fig 2). These two tumours were classified as Luminal
B and had very few other genomic aberrations, none of which
were in common, providing compelling evidence for ZNF703
amplification being an early driver event in both tumours.
Importantly, IHC shows ZNF703 (nuclear) protein in breast
cancer cells is concomitantly increased with gene copy number/
expression (Fig S2E and F), as predicted for an oncoprotein. 2011 EMBO Molecular Medicine 175
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Figure 6. ZNF703 expression affects progenitors in normal mammary
epithelium.
A. FACS plot of one of the primary mammary epithelium single cell
suspensions showing the gating used to isolate the Luminal-enriched
fraction (A) and Basal-enriched fraction (B).
B. CFC assay data bivariate plot. X-axis shows the number of colonies counted
under the control condition (empty vector). Y-axis shows the number of
colonies counted under the experimental condition (vector containing
ZNF703 construct). Black reference line has slope¼1.0 and intercept¼0.
Solid lines show full linear model fit results. Dashed lines show linear
model fits with intercept constrained to be zero.
C. CFC assay results with chart showing colony count fold change with
ZNF703 overexpression in Luminal-enriched (A) or Basal-enriched
(B) sorted fractions relative to the empty vector control condition. Vertical
bars represent 95% confidence intervals (n¼ 6).
176Although ZNF703 expression in ERþ tumours was mostly copy
number-driven, the gene was also highly expressed in a subset
of ERþ luminal cancers without 8p12 amplification (Fig S2).
These cases were disproportionately of the Luminal B subtype,
suggesting that ZNF703 could be deregulated in these tumours
by alternative mechanisms. One such mechanismmight involve
modulation of oestrogen responsiveness, given that ZNF703 has 2011 EMBO Molecular Medicinea conserved ER-binding site active in ERþ breast cancer cell
lines and primary tumours [(Lin et al, 2007) and J. Carroll,
unpublished observations], and ZNF703 is an ER-responsive
gene (data not shown). Indeed, we have identified a robust lipid
metabolism and detoxification signature characteristic of
Luminal B ZNF703-amplified or -overexpressing tumours that
is conserved in luminal cell lines (Figs 3 and S3). Numerous
oestrogen metabolizing enzymes including the UDP glucur-
onosyltransferases (UGT2B7 and UGT2B11), glutathione-S-
transferases (GSTP1, GSTT1, MGST1), ACOX2, and HMGCS2
were found to be co-ordinately downregulated in this pathway,
which converges upon DHRS2/Hep27, a short chain dehydro-
genase implicated in cytochrome P450 xenobiotic metabolism.
Taken together, these observations suggest a possible role for
ZNF703 in modulating oestrogen metabolism in luminal
tumours.
An important observation that arises from our data is that
ZNF703 and ERBB2 amplifications (which are almost completely
mutually exclusive) jointly account for around 2/3 of all breast
cancers of the Luminal B subtype (Fig S2). This has potential for
clinical application since a combination of IHC and FISH for
these two genes/proteins (ZNF703 and ERBB2) can now be used
to identify these more aggressive ERþ cancers in the clinic.
A critical step in the validation of ZNF703 as a candidate
oncogene was its ability to endow the NIH 3T3 non-neoplastic
mouse fibroblast cells with the growth properties characteristic
of cancer cells (Fig 4A and B). The focus formation assay is the
classical transformation assay that was used to identify the first
human oncogenes (Shih & Weinberg, 1982; Goldfarb et al,
1982). Transformation of epithelial cells is much more difficult
but we were able to demonstrate that ZNF703 regulates
proliferation in established human (luminal) breast cancer cell
lines and in immortalized normal human mammary epithelium
(Fig 4C–E). We note that a previous report demonstrated the
ability of ZNF703 to transform breast epithelial cells expressing a
dominant negative mutant of TP53 (Kwek et al, 2009). All of
these observations provide compelling evidence to support
ZNF703 as the driver oncogene of the distal 8p12 amplicon.
The ability of ZNF703 to regulate proliferation could
potentially be explained by a pro-proliferation transcriptional
program and prompted us to profile MCF7 cells with over-
expression or knockdown of ZNF703 using gene expressionEMBO Mol Med 3, 167–180 www.embomolmed.org
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expression of CDKN2B with ZNF703 overexpression and
marginal, but RT-qPCR verified, differential expression of
TGFBR2with ZNF703manipulation. Both genes encode proteins
in the canonical TGFb pathway: one of the key receptors for
TGFb, TGFBR2, and a downstream target, the cell cycle inhibitor
CDKNB2. TGFb is a potent inhibitor of proliferation in MCF7
cells and hence we conducted experiments to investigate
whether the TGFb pathway could be modulated by altering
ZNF703 expression. Although our data are of a preliminary
nature, we note that in MCF7 cells with ZNF703 overexpression
treated with TGFb, there was less activation of the pathway as
measured by RT-qPCR of target genes (TGFBI and PAI1), in
association with abrogation of effect on proliferation (Fig 5B). In
the inverse experiment, we showed that in MCF7 cells with
ZNF703 knockdown, inhibition of TGFb signalling rescues the
effect on BrdU incorporation (Fig 5C), suggesting that upon
ZNF703 knockdown there is unopposed TGFb-pathway signal-
ling. We saw binding of ZNF703 to regulatory sequences of
TGFBR2 (Fig 5D), with consequent repression of transcription.
This could in part explain the observed modulation.
In experiments conducted in primary normal mammary
epithelium isolated from 6 independent woman, we showed that
ZNF703 overexpression consistently favours the luminal
differentiation pathway (Fig 6), suggesting a mechanistic link
with the almost exclusive selection of amplifications in luminal
tumours. There are several putative explanations for the
increased colony numbers seen in the luminal progenitor cell
population transduced with lenti-ZNF703. The most parsimo-
nious explanation, given our observations that ZNF703 over-
expression regulates proliferation, is that ZNF703 differentially
regulates cell cycle in luminal/or bipotent progenitor cells. An
alternative explanation, namely back recruitment of cells in
early lineage commitment, could not be supported experimen-
tally as transduction of differentiated EpCamþ CD49 luminal
cells with lenti-ZNF703 did not induce colony formation in this
population (data not shown).
The evolutionary conservation of ZNF703 provides some
clues about possible molecular mechanism that should be
explored in future experiments. ZNF703 is the human ortholog
of zebrafish (Danio rerio, Dr) Nlz1 and together with its
homologue ZNF503, the human ortholog of Dr Nlz2, form a
family of highly evolutionary conserved C2H2 zinc finger genes,
which includes the Drosophila (Drosophila melanogaster, Dm)
genes ElB (elbow) and NocA (no ocelli) (Hoyle et al, 2004).
Family members have a Groucho-binding motif, display nuclear
localization and are directly associated with class I histone
deacetylases, suggestive of repressors of transcription (Dorfman
et al, 2002; Runko & Sagerstrom, 2004). Indeed, Nlz1/ZNF703
and Nlz2/ZNF503 repress transcription both in mammalian cell
lines (human, rat and mouse) and in developing Dr embryos
(Nakamura et al, 2008). Both Nlz1 and Nlz2 are capable of
binding the PAX2 promoter, inhibiting PAX2 promoter-driven
expression of luciferase in human cells (Brown et al, 2009). In
Dm, there is parallel activity of ElB/NocA and the Dpp pathway
(Dorfman et al, 2002), the homologue of the vertebrate bone
morphogenetic proteins (BMPs), which are members of thewww.embomolmed.org EMBO Mol Med 3, 167–180TGFb superfamily. We have obtained preliminary evidence that
ZNF703 (and ZNF503) co-immunoprecipitates with ER in the
nucleus along with Groucho homologues, HDAC1 and HDAC2
(J. Carroll, unpublished observations). Future experiments will
address what is the interplay among ZNF703, ER and chromatin
repression.
Recently murine znf703 (Zeppo1) has been shown to be a
regulator of cell adhesion, migration, and proliferation in
mammary epithelial cells (Slorach et al, 2011). In addition, these
authors showed Zeppo1 regulates transcription, repressing E-
cadherin expression and Wnt and TGBb reporter expression.
In summary, the data presented here can be considered in
light of the recently proposed weight-of-evidence based
classification system for identifying individual genes in
amplified regions that are selected for during tumour develop-
ment (Santarius et al, 2010). Using this framework, ZNF703
qualifies as only the 13th Class II oncogene, scoring in 3 out of 4
types of supporting evidence:(i) Clinical correlation: ZNF703 amplification is associated
with a distinct subtype (Luminal B breast cancer) and with
worse clinical outcome in ERþ cancers. ZNF703 amplifica-
tion is associated with higher grade and more aggressive
tumours, explaining the worse clinical prognosis.(ii) Genetic/genomic information: ZNF703 is the sole gene in
the amplicon in two independent primary tumours, and its
amplification leads to transcript and protein overexpres-
sion, as predicted for a classical oncogene.(iii) Biological evidence: ZNF703 overexpression causes a
biological effect with transforming activity in the classical
NIH 3T3 focus formation and soft agar assays, regulation of
proliferation in breast epithelial cells lines and differential
regulation of progenitors in primary human mammary
epithelium (showing pro-luminal activity).An accompanying study (Sircoulomb et al, 2011) provides
independent validation of some of our central findings: ZNF703
is predominantly amplified in Luminal B cancers, its expression
regulates cell proliferation, and it is involved in modulating
oestrogen response. The two manuscripts in our view provide
definitive evidence for ZNF703 as a novel human breast cancer
oncogene.MATERIALS AND METHODS
Tumour and cell line samples for molecular profiling
We used two series of tumours for the analyses described here and
these were obtained with appropriate consent and the studies
approved by the relevant ethics boards.
The ‘NT-series’ was a set of 171 tumours (and 6 normal patient
samples) previously described by our group in several molecular
profiling studies (Blenkiron et al, 2007; Chin et al, 2007). (ArrayExpress
accession: E-TABM-576). A set of 49 breast cancer cell lines were also
profiled at the genomic level, 39 of which were also assayed at the
mRNA level (Chin et al, 2007 and unpublished data) (ArrayExpress
accession: E-TABM-827). 2011 EMBO Molecular Medicine 177
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The paper explained
PROBLEM:
Despite their better overall prognosis, the survival rates of
patients with ER-positive breast cancers are extremely variable
and identifying biomarkers and drivers of poor outcome is an
important step to improve clinical management. Luminal B
breast cancers are the clinically more aggressive ER-positive
tumours and characterizing the genomic drivers (oncogenes) at
chromosomal loci frequently altered in this subtype has been the
subject of intense research.
RESULTS:
Here, we characterize ZNF703 as the driver of the frequent
amplification of a distal 8p12 locus, which occurs in around 1/3
of Luminal B breast cancers, less frequently in other ER-positive
tumours and uncommonly in ER-negative tumours. ZNF703
behaves as a classical oncogene in that it transforms non-
malignant cells and increases cellular proliferation. The ampli-
fication of the gene is accompanied by overexpression of the
encoded protein, which can be observed using immunostaining
of tissue sections, making its detection in routine histopathology
laboratories possible.
IMPACT:
ZNF703 is a new breast cancer oncogene and a potential
prognostic biomarker and therapeutic target in the more
aggressive ER-positive breast cancers.
178The ‘MB-series’ refers to a set of 1001 tumours with a minimum of 5
years of clinical follow up (Curtis et al, manuscript in preparation) that
are broadly representative of a population-based collection (75%
ERþ). For this cohort, mRNA was hybridized to Illumina HT-12
BeadArrays, and copy number was assayed on the Affymetrix SNP 6.0
platform (data available through the European Genotype Archive—
http://www.ebi.ac.uk/ega/page.php under Accession Number:
EGAS00000000082).
Briefly, samples were classified into the intrinsic subtypes based on the
PAM50 gene list (Parker et al, 2009). A description of the normal-
ization, segmentation, and statistical analyses is available in Support-
ing information. Pathway-based analysis was carried out using
Ingenuity Pathways Analysis (Ingenuity1 Systems, www.ingenuity.
com).
Real time PCR
RT-qPCR was performed on the ABI Prism 7900HT sequence detection
system (Applied Biosystems) using SYBR1 Green reporter. All the
samples were analysed as triplicates and some runs were repeated to
assess the robustness. Details are provided in Supporting information.
NIH 3T3 transformation assays
hZNF703 and mKrasG12D4B cDNAs were cloned into pBabe-hygro
(Addgene plasmid 1765) or pBabe-puro, respectively. NIH 3T3 cells
were infected with retroviruses produced in Phoenix packaging cells
and were selected with puromycin or hygromycin. Experiments were
performed using 2 independent NIH 3T3 infected pools. For the
proliferation assay NIH 3T3 cells were plated in triplicates in 12-well
plates and counted every day for 4 days. For the focus formation
assay, cells were plated in duplicates, cultured until confluence
and a week later stained. Details are provided in Supporting
information. Anchorage independent growth assay used colony
formation in soft agar. Briefly, 25,000 cells were plated in duplicates
in DMEM with 15% serum and 0.34% low-melting point agarose
(LMP, BioGene) onto 6-cm dishes coated with 0.5% LMP. Cells were
grown for 4 weeks. 2011 EMBO Molecular MedicineManipulation of ZNF703 levels in MCF7 cells
For knock-down experiments, sub-confluent MCF7 cultures were
transfected with 100nM either a si-ZNF703 pool targeting the 30UTR
of endogenous ZNF703 or a non-targeting siRNA (si-control) using
Lipofectamine 2000 (Invitrogen). For overexpression experiments, sub-
confluent MCF7 cultures were infected twice on consecutive days with
either lenti-control (HIV-ZsGreen; Welm et al, 2008) or lenti-ZNF703
containing the entire ZNF703 coding sequence, and sorted by GFP
expression to eliminate non-infected cells. Protein, total RNA and
chromatin were extracted from replicate samples.
ZNF703 and beta-actin protein levels were assessed by Western blot
analysis. Total RNA was analysed by RT-QPCR and Illumina HT-12
BeadArrays (data available through the NCBI’s Gene Expression
Omnibus—http://www.ncbi.nlm.nih.gov/geo/through GEO Series ac-
cession number GSE23673). Chromatin was immunoprecipitated as in
(Schmidt et al, 2009) using anti-ZNF703, anti-p300 or anti-HDAC1
antibodies and analysed by QPCR. Detailed experimental description,
primer sequences and statistical analyses are available in Supporting
information.
TGFb-pathway modulation
Recombinant human TGFb1 (R&D systems) was added to cell
culture at a final concentration of 2.5 ng/ml. SB-431542 (Sigma)
inhibitor of TbRI was added to cell culture at a final concentration of
10mM.
BrdU incorporation assay
Cells were pulsed with 10mM BrdU (Sigma) for 1 h (MCF7) or 4 h
(HCC1500). Cells were detached with trypsin, fixed in 75% ethanol
and treated as follows (PBS with 0.5% BSA washes between each
step): 2M HCl; 0.1M sodium borate pH 8.5; FITC-conjugated anti-
BrdU (BD Biosciences) diluted 1:5 in PBS with 0.5% BSA and 0.5%
Tween20 for 1 h at room temperature; finally, PBS with 5mg/ml
propidium iodide, 0.1mg/ml RNAse A and 0.1% Triton X-100. Samples
were analysed by two-dimensional flow cytometry to detect both
fluorescein and propidium iodide.EMBO Mol Med 3, 167–180 www.embomolmed.org
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epithelial cells
The 184-hTERT-L9 immortalized normal mammary epithelial cell lines
were infected with freshly thawed lentiviral particles and Zsgreen
positive cells were expanded and subsequently subjected to cell cycle
and ZNF703 expression analysis. For details see Supporting information.
ZNF703 overexpression in primary human mammary
epithelium
Discarded tissue was collected with informed consent from pre-
menopausal women (ages 19–40) undergoing reduction mammo-
plasty surgery as approved by the University of British Columbia
Research Ethics Board. Post-collection processing was performed as
previously described (Stingl et al, 2005) to generate a cryopreserved
epithelial-cell rich pellet. Single cell suspensions from freshly thawed
pellets were subjected to basal and luminal population discrimination
by FACS-sorting using an allophycocyanin-conjugated rat antibody to
human CD49f and a phycoerythrin-conjugated mouse antibody to
human EpCam, respectively (Eirew et al, 2008). Haematopoietic and
endothelial cells were eliminated using antibodies to human CD45
and human CD31, respectively.
Sorted populations of primary HMECs were immediately infected with
freshly thawed lenti-control or lenti-ZNF703 virus at an estimated
multiplicity of infection (MOI) of 3. After 18 h at 378C, equal numbers
of cells were plated in CFC assays performed as previously described
(Raouf et al, 2008) and upon methylene blue staining, colonies with
50 cells or more were visually scored under a dissecting microscope.
For details of tissue processing, FACS sorting, transduction, CFC assays
and associated statistical analyses, see Supporting information.Author contributions
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